<?xml version="1.0" encoding="utf-8"?><api:response xmlns:api="http://www.symplectic.co.uk/publications/api"><api:version uri="https://mypublications.shef.ac.uk/" elements-version="6.15.0.3976" schema-version="6.13" product-name="myPublications"/><api:request href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/publications/854"/><api:result><api:object category="publication" id="854" last-affected-when="2024-03-14T05:57:11.243+00:00" last-modified-when="2024-03-14T05:57:11.243+00:00" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/publications/854" created-when="2010-05-17T13:46:30.893+01:00" type-id="5" type-display-name="Journal article" type="journal-article"><api:privacy-level>Public</api:privacy-level><api:privacy-level-locked>false</api:privacy-level-locked><api:ever-approved>true</api:ever-approved><api:reporting-date-1>2000-04-01</api:reporting-date-1><api:allow-type-switching>true</api:allow-type-switching><api:records><api:record format="native" id="2539351" source-id="13" source-name="crossref" source-display-name="Crossref" id-at-source="10.3892/ijo.16.4.777" last-modified-when="2022-09-11T04:35:04.39+01:00"><api:native><api:field name="authors" type="person-list" display-name="Authors"><api:people><api:person><api:last-name>El Helw</api:last-name><api:initials>LM</api:initials><api:first-names>LM</api:first-names><api:separate-first-names><api:first-name>L</api:first-name><api:first-name>M</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Lorigan</api:last-name><api:initials>PC</api:initials><api:first-names>PC</api:first-names><api:separate-first-names><api:first-name>P</api:first-name><api:first-name>C</api:first-name></api:separate-first-names></api:person><api:person><api:links><api:link type="elements/user" id="1603" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/1603"/></api:links><api:last-name>Robinson</api:last-name><api:initials>MH</api:initials><api:first-names>MH</api:first-names><api:separate-first-names><api:first-name>M</api:first-name><api:first-name>H</api:first-name></api:separate-first-names></api:person><api:person><api:links><api:link type="elements/user" id="1991" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/1991"/></api:links><api:last-name>Coleman</api:last-name><api:initials>RE</api:initials><api:first-names>RE</api:first-names><api:separate-first-names><api:first-name>R</api:first-name><api:first-name>E</api:first-name></api:separate-first-names></api:person><api:person><api:links><api:link type="elements/user" id="18786" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/18786"/></api:links><api:last-name>Hancock</api:last-name><api:initials>BW</api:initials><api:first-names>BW</api:first-names><api:separate-first-names><api:first-name>B</api:first-name><api:first-name>W</api:first-name></api:separate-first-names></api:person></api:people></api:field><api:field name="doi" type="text" display-name="DOI"><api:text>10.3892/ijo.16.4.777</api:text><api:links><api:link type="doi" href="http://doi.org/10.3892/ijo.16.4.777"/><api:link type="altmetric" href="http://www.altmetric.com/details.php?doi=10.3892/ijo.16.4.777"/></api:links></api:field><api:field name="eissn" type="text" display-name="eISSN"><api:text>1791-2423</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/974000"/></api:links></api:field><api:field name="issn" type="text" display-name="ISSN"><api:text>1019-6439</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/974000"/></api:links></api:field><api:field name="journal" type="text" display-name="Journal"><api:text>International Journal of Oncology</api:text></api:field><api:field name="online-publication-date" type="date" display-name="Online publication date"><api:date><api:day>1</api:day><api:month>4</api:month><api:year>2000</api:year></api:date></api:field><api:field name="publication-status" type="text" display-name="Status"><api:text>Published online</api:text></api:field><api:field name="publisher" type="text" display-name="Publisher"><api:text>Spandidos Publications</api:text></api:field><api:field name="publisher-url" type="text" display-name="Link 2"><api:text>http://dx.doi.org/10.3892/ijo.16.4.777</api:text></api:field><api:field name="record-created-at-source-date" type="date" display-name="Record created at source"><api:date><api:day>27</api:day><api:month>4</api:month><api:year>2017</api:year></api:date></api:field><api:field name="title" type="text" display-name="Title"><api:text>VEDex (vincristine, epirubicin dexamethasone): an effective and well tolerated palliative chemotherapy regimen for non-Hodgkin's lymphoma.</api:text></api:field></api:native></api:record><api:record format="native" id="96056" source-id="7" source-name="scopus" source-display-name="Scopus" id-at-source="2-s2.0-0034164542" last-modified-when="2020-08-19T20:54:47.313+01:00"><api:citation-count>5</api:citation-count><api:native><api:field name="abstract" type="text" display-name="Abstract"><api:text>An evaluation was carried out of the efficacy and toxicity of a novel weekly palliative chemotherapy regimen comprising vincristine, epirubicin and dexamethasone (VEDex) in 57 patients with non-Hodgkin's lymphoma (NHL) treated at this centre. The age range was 34-88 years and the median age was 67 years. Twenty-three patients (40%) had low grade disease and 4 patients (7%) had transformed NHL. Thirty patients (53%) had high grade NHL; 7 had relapsed after conventional chemotherapy and were not fit for high-dose chemotherapy, 7 were heavily pre-treated, 8 had received prior radiotherapy and 8 had not received any prior therapy. Responding patients received a total of 8 weeks of treatment, but treatment could be repeated at a later stage if required. The overall response rate was 66.6%; 11 patients (19.3%) achieved a complete response and 27 (47.3%) achieved a partial response. A further 11 patients (19.3%) had stable disease. Twenty-four patients (42.1%) reported complete resolution of symptoms and 21 (36.8%) had partial resolution of symptoms. The median survival from the onset of treatment was 6 months. Grade III neutropenia was seen in 9 patients (15.8%). Other toxicity included nausea and vomiting grade II (3.5%), grade III (1.8%) and alopecia grade III (1.8%). There were no treatment related deaths. We conclude that VEDex is an effective palliative treatment in patients with indolent or aggressive lymphoma with poor performance status or who have been heavily pre-treated. It is well tolerated in the elderly.</api:text></api:field><api:field name="authors" type="person-list" display-name="Authors"><api:people><api:person><api:last-name>El Helw</api:last-name><api:initials>LM</api:initials><api:first-names>LM</api:first-names><api:separate-first-names><api:first-name>L</api:first-name><api:first-name>M</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="GB"><api:line type="organisation">Weston Park Cancer Centre</api:line><api:line type="city">Sheffield</api:line><api:line type="country">United Kingdom</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="scopus-author-id">8867242000</api:identifier></api:identifiers></api:person><api:person><api:last-name>Lorigan</api:last-name><api:initials>PC</api:initials><api:first-names>PC</api:first-names><api:separate-first-names><api:first-name>P</api:first-name><api:first-name>C</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="GB"><api:line type="organisation">Weston Park Cancer Centre</api:line><api:line type="city">Sheffield</api:line><api:line type="country">United Kingdom</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="scopus-author-id">6604053967</api:identifier></api:identifiers></api:person><api:person><api:links><api:link type="elements/user" id="1603" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/1603"/></api:links><api:last-name>Robinson</api:last-name><api:initials>MH</api:initials><api:first-names>MH</api:first-names><api:separate-first-names><api:first-name>M</api:first-name><api:first-name>H</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="GB"><api:line type="organisation">Weston Park Cancer Centre</api:line><api:line type="city">Sheffield</api:line><api:line type="country">United Kingdom</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="scopus-author-id">35553750100</api:identifier></api:identifiers></api:person><api:person><api:links><api:link type="elements/user" id="1991" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/1991"/></api:links><api:last-name>Coleman</api:last-name><api:initials>RE</api:initials><api:first-names>RE</api:first-names><api:separate-first-names><api:first-name>R</api:first-name><api:first-name>E</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="GB"><api:line type="organisation">Weston Park Cancer Centre</api:line><api:line type="city">Sheffield</api:line><api:line type="country">United Kingdom</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="scopus-author-id">7403206142</api:identifier></api:identifiers></api:person><api:person><api:links><api:link type="elements/user" id="18786" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/18786"/></api:links><api:last-name>Hancock</api:last-name><api:initials>BW</api:initials><api:first-names>BW</api:first-names><api:separate-first-names><api:first-name>B</api:first-name><api:first-name>W</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="GB"><api:line type="organisation">Weston Park Cancer Centre</api:line><api:line type="city">Sheffield</api:line><api:line type="country">United Kingdom</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="scopus-author-id">35109059400</api:identifier></api:identifiers></api:person></api:people></api:field><api:field name="doi" type="text" display-name="DOI"><api:text>10.3892/ijo.16.4.777</api:text><api:links><api:link type="doi" href="http://doi.org/10.3892/ijo.16.4.777"/><api:link type="altmetric" href="http://www.altmetric.com/details.php?doi=10.3892/ijo.16.4.777"/></api:links></api:field><api:field name="external-identifiers" type="identifier-list" display-name="External identifiers"><api:identifiers><api:identifier scheme="pubmed">10717248</api:identifier></api:identifiers></api:field><api:field name="issn" type="text" display-name="ISSN"><api:text>1019-6439</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/974000"/></api:links></api:field><api:field name="issue" type="text" display-name="Issue"><api:text>4</api:text></api:field><api:field name="journal" type="text" display-name="Journal"><api:text>International journal of oncology</api:text></api:field><api:field name="pagination" type="pagination" display-name="Pagination"><api:pagination><api:begin-page>777</api:begin-page><api:end-page>782</api:end-page></api:pagination></api:field><api:field name="publication-date" type="date" display-name="Publication date"><api:date><api:day>1</api:day><api:month>1</api:month><api:year>2000</api:year></api:date></api:field><api:field name="publication-status" type="text" display-name="Status"><api:text>Published</api:text></api:field><api:field name="title" type="text" display-name="Title"><api:text>VEDex (vincristine, epirubicin dexamethasone): an effective and well tolerated palliative chemotherapy regimen for non-Hodgkin's lymphoma.</api:text></api:field><api:field name="types" type="list" display-name="Sub types"><api:items><api:item>Journal Article</api:item></api:items></api:field><api:field name="volume" type="text" display-name="Volume"><api:text>16</api:text></api:field></api:native></api:record><api:record format="native" id="854" source-id="2" source-name="pubmed" source-display-name="PubMed" id-at-source="10717248" last-modified-when="2020-04-29T05:33:15.95+01:00"><api:native><api:field name="abstract" type="text" display-name="Abstract"><api:text>An evaluation was carried out of the efficacy and toxicity of a novel weekly palliative chemotherapy regimen comprising vincristine, epirubicin and dexamethasone (VEDex) in 57 patients with non-Hodgkin's lymphoma (NHL) treated at this centre. The age range was 34-88 years and the median age was 67 years. Twenty-three patients (40%) had low grade disease and 4 patients (7%) had transformed NHL. Thirty patients (53%) had high grade NHL; 7 had relapsed after conventional chemotherapy and were not fit for high-dose chemotherapy, 7 were heavily pre-treated, 8 had received prior radiotherapy and 8 had not received any prior therapy. Responding patients received a total of 8 weeks of treatment, but treatment could be repeated at a later stage if required. The overall response rate was 66.6%; 11 patients (19.3%) achieved a complete response and 27 (47.3%) achieved a partial response. A further 11 patients (19.3%) had stable disease. Twenty-four patients (42.1%) reported complete resolution of symptoms and 21 (36.8%) had partial resolution of symptoms. The median survival from the onset of treatment was 6 months. Grade III neutropenia was seen in 9 patients (15.8%). Other toxicity included nausea and vomiting grade II (3.5%), grade III (1.8%) and alopecia grade III (1.8%). There were no treatment related deaths. We conclude that VEDex is an effective palliative treatment in patients with indolent or aggressive lymphoma with poor performance status or who have been heavily pre-treated. It is well tolerated in the elderly.</api:text></api:field><api:field name="authors" type="person-list" display-name="Authors"><api:people><api:person><api:last-name>El Helw</api:last-name><api:initials>LM</api:initials><api:first-names>LM</api:first-names><api:separate-first-names><api:first-name>L</api:first-name><api:first-name>M</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="GB"><api:line type="full">Yorkshire Cancer Research Section of Clinical Oncology, Weston Park Hospital, Sheffield S10 2SJ, UK.</api:line></api:address></api:addresses></api:person><api:person><api:last-name>Lorigan</api:last-name><api:initials>PC</api:initials><api:first-names>PC</api:first-names><api:separate-first-names><api:first-name>P</api:first-name><api:first-name>C</api:first-name></api:separate-first-names></api:person><api:person><api:links><api:link type="elements/user" id="1603" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/1603"/></api:links><api:last-name>Robinson</api:last-name><api:initials>MH</api:initials><api:first-names>MH</api:first-names><api:separate-first-names><api:first-name>M</api:first-name><api:first-name>H</api:first-name></api:separate-first-names></api:person><api:person><api:links><api:link type="elements/user" id="1991" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/1991"/></api:links><api:last-name>Coleman</api:last-name><api:initials>RE</api:initials><api:first-names>RE</api:first-names><api:separate-first-names><api:first-name>R</api:first-name><api:first-name>E</api:first-name></api:separate-first-names></api:person><api:person><api:links><api:link type="elements/user" id="18786" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/18786"/></api:links><api:last-name>Hancock</api:last-name><api:initials>BW</api:initials><api:first-names>BW</api:first-names><api:separate-first-names><api:first-name>B</api:first-name><api:first-name>W</api:first-name></api:separate-first-names></api:person></api:people></api:field><api:field name="author-url" type="text" display-name="Link 1"><api:text>https://www.ncbi.nlm.nih.gov/pubmed/10717248</api:text></api:field><api:field name="doi" type="text" display-name="DOI"><api:text>10.3892/ijo.16.4.777</api:text><api:links><api:link type="doi" href="http://doi.org/10.3892/ijo.16.4.777"/><api:link type="altmetric" href="http://www.altmetric.com/details.php?doi=10.3892/ijo.16.4.777"/></api:links></api:field><api:field name="issn" type="text" display-name="ISSN"><api:text>1019-6439</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/974000"/></api:links></api:field><api:field name="issue" type="text" display-name="Issue"><api:text>4</api:text></api:field><api:field name="journal" type="text" display-name="Journal"><api:text>Int J Oncol</api:text></api:field><api:field name="keywords" type="keyword-list" display-name="Keywords"><api:keywords><api:keyword scheme="mesh">Adult</api:keyword><api:keyword scheme="mesh">Aged</api:keyword><api:keyword scheme="mesh">Aged, 80 and over</api:keyword><api:keyword scheme="mesh">Antineoplastic Combined Chemotherapy Protocols</api:keyword><api:keyword scheme="mesh">Dexamethasone</api:keyword><api:keyword scheme="mesh">Epirubicin</api:keyword><api:keyword scheme="mesh">Female</api:keyword><api:keyword scheme="mesh">Humans</api:keyword><api:keyword scheme="mesh">Lymphoma, Non-Hodgkin</api:keyword><api:keyword scheme="mesh">Male</api:keyword><api:keyword scheme="mesh">Middle Aged</api:keyword><api:keyword scheme="mesh">Palliative Care</api:keyword><api:keyword scheme="mesh">Vincristine</api:keyword></api:keywords></api:field><api:field name="language" type="text" display-name="Language"><api:text>eng</api:text></api:field><api:field name="location" type="text" display-name="Country"><api:text>Greece</api:text></api:field><api:field name="pagination" type="pagination" display-name="Pagination"><api:pagination><api:begin-page>777</api:begin-page><api:end-page>782</api:end-page></api:pagination></api:field><api:field name="publication-date" type="date" display-name="Publication date"><api:date><api:month>4</api:month><api:year>2000</api:year></api:date></api:field><api:field name="publication-status" type="text" display-name="Status"><api:text>Published</api:text></api:field><api:field name="record-made-public-at-source-date" type="date" display-name="Record made publicly available"><api:date><api:day>11</api:day><api:month>5</api:month><api:year>2000</api:year></api:date></api:field><api:field name="title" type="text" display-name="Title"><api:text>VEDex (vincristine, epirubicin dexamethasone): an effective and well tolerated palliative chemotherapy regimen for non-Hodgkin's lymphoma.</api:text></api:field><api:field name="types" type="list" display-name="Sub types"><api:items><api:item>Journal Article</api:item></api:items></api:field><api:field name="volume" type="text" display-name="Volume"><api:text>16</api:text></api:field></api:native></api:record><api:record format="native" id="882091" source-id="18" source-name="epmc" source-display-name="Europe PubMed Central" id-at-source="MED:10717248" last-modified-when="2020-06-09T17:56:54.98+01:00"><api:citation-count>5</api:citation-count><api:native><api:field name="abstract" type="text" display-name="Abstract"><api:text>An evaluation was carried out of the efficacy and toxicity of a novel weekly palliative chemotherapy regimen comprising vincristine, epirubicin and dexamethasone (VEDex) in 57 patients with non-Hodgkin's lymphoma (NHL) treated at this centre. The age range was 34-88 years and the median age was 67 years. Twenty-three patients (40%) had low grade disease and 4 patients (7%) had transformed NHL. Thirty patients (53%) had high grade NHL; 7 had relapsed after conventional chemotherapy and were not fit for high-dose chemotherapy, 7 were heavily pre-treated, 8 had received prior radiotherapy and 8 had not received any prior therapy. Responding patients received a total of 8 weeks of treatment, but treatment could be repeated at a later stage if required. The overall response rate was 66.6%; 11 patients (19.3%) achieved a complete response and 27 (47.3%) achieved a partial response. A further 11 patients (19.3%) had stable disease. Twenty-four patients (42.1%) reported complete resolution of symptoms and 21 (36.8%) had partial resolution of symptoms. The median survival from the onset of treatment was 6 months. Grade III neutropenia was seen in 9 patients (15.8%). Other toxicity included nausea and vomiting grade II (3.5%), grade III (1.8%) and alopecia grade III (1.8%). There were no treatment related deaths. We conclude that VEDex is an effective palliative treatment in patients with indolent or aggressive lymphoma with poor performance status or who have been heavily pre-treated. It is well tolerated in the elderly.</api:text></api:field><api:field name="addresses" type="address-list" display-name="Addresses"><api:addresses><api:address iso-country-code="GB"><api:line type="full">Yorkshire Cancer Research Section of Clinical Oncology, Weston Park Hospital, Sheffield S10 2SJ, UK.</api:line></api:address></api:addresses></api:field><api:field name="authors" type="person-list" display-name="Authors"><api:people><api:person><api:last-name>El Helw</api:last-name><api:initials>LM</api:initials><api:first-names>LM</api:first-names><api:separate-first-names><api:first-name>L</api:first-name><api:first-name>M</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Lorigan</api:last-name><api:initials>PC</api:initials><api:first-names>PC</api:first-names><api:separate-first-names><api:first-name>P</api:first-name><api:first-name>C</api:first-name></api:separate-first-names><api:identifiers><api:identifier scheme="orcid">0000-0002-8875-2164</api:identifier></api:identifiers></api:person><api:person><api:links><api:link type="elements/user" id="1603" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/1603"/></api:links><api:last-name>Robinson</api:last-name><api:initials>MH</api:initials><api:first-names>MH</api:first-names><api:separate-first-names><api:first-name>M</api:first-name><api:first-name>H</api:first-name></api:separate-first-names></api:person><api:person><api:links><api:link type="elements/user" id="1991" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/1991"/></api:links><api:last-name>Coleman</api:last-name><api:initials>RE</api:initials><api:first-names>RE</api:first-names><api:separate-first-names><api:first-name>R</api:first-name><api:first-name>E</api:first-name></api:separate-first-names></api:person><api:person><api:links><api:link type="elements/user" id="18786" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/18786"/></api:links><api:last-name>Hancock</api:last-name><api:initials>BW</api:initials><api:first-names>BW</api:first-names><api:separate-first-names><api:first-name>B</api:first-name><api:first-name>W</api:first-name></api:separate-first-names></api:person></api:people></api:field><api:field name="doi" type="text" display-name="DOI"><api:text>10.3892/ijo.16.4.777</api:text><api:links><api:link type="doi" href="http://doi.org/10.3892/ijo.16.4.777"/><api:link type="altmetric" href="http://www.altmetric.com/details.php?doi=10.3892/ijo.16.4.777"/></api:links></api:field><api:field name="eissn" type="text" display-name="eISSN"><api:text>1791-2423</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/974000"/></api:links></api:field><api:field name="external-identifiers" type="identifier-list" display-name="External identifiers"><api:identifiers><api:identifier scheme="pubmed">10717248</api:identifier></api:identifiers></api:field><api:field name="is-open-access" type="boolean" display-name="Open access"><api:boolean>false</api:boolean></api:field><api:field name="issn" type="text" display-name="ISSN"><api:text>1019-6439</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/974000"/></api:links></api:field><api:field name="issue" type="text" display-name="Issue"><api:text>4</api:text></api:field><api:field name="journal" type="text" display-name="Journal"><api:text>International journal of oncology</api:text></api:field><api:field name="keywords" type="keyword-list" display-name="Keywords"><api:keywords><api:keyword scheme="mesh">Humans</api:keyword><api:keyword scheme="mesh">Lymphoma, Non-Hodgkin</api:keyword><api:keyword scheme="mesh">Vincristine</api:keyword><api:keyword scheme="mesh">Epirubicin</api:keyword><api:keyword scheme="mesh">Dexamethasone</api:keyword><api:keyword scheme="mesh">Antineoplastic Combined Chemotherapy Protocols</api:keyword><api:keyword scheme="mesh">Palliative Care</api:keyword><api:keyword scheme="mesh">Adult</api:keyword><api:keyword scheme="mesh">Aged</api:keyword><api:keyword scheme="mesh">Aged, 80 and over</api:keyword><api:keyword scheme="mesh">Middle Aged</api:keyword><api:keyword scheme="mesh">Female</api:keyword><api:keyword scheme="mesh">Male</api:keyword></api:keywords></api:field><api:field name="language" type="text" display-name="Language"><api:text>eng</api:text></api:field><api:field name="medium" type="text" display-name="Medium"><api:text>Print</api:text></api:field><api:field name="pagination" type="pagination" display-name="Pagination"><api:pagination><api:begin-page>777</api:begin-page><api:end-page>782</api:end-page></api:pagination></api:field><api:field name="publication-date" type="date" display-name="Publication date"><api:date><api:month>4</api:month><api:year>2000</api:year></api:date></api:field><api:field name="publication-status" type="text" display-name="Status"><api:text>Published</api:text></api:field><api:field name="record-created-at-source-date" type="date" display-name="Record created at source"><api:date><api:day>16</api:day><api:month>3</api:month><api:year>2000</api:year></api:date></api:field><api:field name="title" type="text" display-name="Title"><api:text>VEDex (vincristine, epirubicin dexamethasone): an effective and well tolerated palliative chemotherapy regimen for non-Hodgkin's lymphoma.</api:text></api:field><api:field name="types" type="list" display-name="Sub types"><api:items><api:item>Journal Article</api:item></api:items></api:field><api:field name="volume" type="text" display-name="Volume"><api:text>16</api:text></api:field></api:native></api:record><api:record format="native" id="2497192" source-id="10" source-name="dimensions" source-display-name="Dimensions" id-at-source="pub.1071511308" last-modified-when="2023-11-27T01:42:14.28+00:00"><api:citation-count>5</api:citation-count><api:native><api:field name="authors" type="person-list" display-name="Authors"><api:people><api:person><api:last-name>El Helw</api:last-name><api:initials>LM</api:initials><api:first-names>LM</api:first-names><api:separate-first-names><api:first-name>L</api:first-name><api:first-name>M</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="GB"><api:line type="organisation">Weston Park Cancer Centre</api:line><api:line type="city">Sheffield</api:line><api:line type="country">United Kingdom</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="dimensions-researcher-id">ur.01156340653.47</api:identifier></api:identifiers></api:person><api:person><api:last-name>Lorigan</api:last-name><api:initials>PC</api:initials><api:first-names>PC</api:first-names><api:separate-first-names><api:first-name>P</api:first-name><api:first-name>C</api:first-name></api:separate-first-names><api:identifiers><api:identifier scheme="dimensions-researcher-id">ur.01223762727.50</api:identifier></api:identifiers></api:person><api:person><api:links><api:link type="elements/user" id="1603" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/1603"/></api:links><api:last-name>Robinson</api:last-name><api:initials>MH</api:initials><api:first-names>MH</api:first-names><api:separate-first-names><api:first-name>M</api:first-name><api:first-name>H</api:first-name></api:separate-first-names><api:identifiers><api:identifier scheme="dimensions-researcher-id">ur.015623726436.86</api:identifier></api:identifiers></api:person><api:person><api:links><api:link type="elements/user" id="1991" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/1991"/></api:links><api:last-name>Coleman</api:last-name><api:initials>RE</api:initials><api:first-names>RE</api:first-names><api:separate-first-names><api:first-name>R</api:first-name><api:first-name>E</api:first-name></api:separate-first-names><api:identifiers><api:identifier scheme="dimensions-researcher-id">ur.014331105607.96</api:identifier></api:identifiers></api:person><api:person><api:links><api:link type="elements/user" id="18786" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/18786"/></api:links><api:last-name>Hancock</api:last-name><api:initials>BW</api:initials><api:first-names>BW</api:first-names><api:separate-first-names><api:first-name>B</api:first-name><api:first-name>W</api:first-name></api:separate-first-names><api:identifiers><api:identifier scheme="dimensions-researcher-id">ur.01257257663.76</api:identifier></api:identifiers></api:person></api:people></api:field><api:field name="doi" type="text" display-name="DOI"><api:text>10.3892/ijo.16.4.777</api:text><api:links><api:link type="doi" href="http://doi.org/10.3892/ijo.16.4.777"/><api:link type="altmetric" href="http://www.altmetric.com/details.php?doi=10.3892/ijo.16.4.777"/></api:links></api:field><api:field name="external-identifiers" type="identifier-list" display-name="External identifiers"><api:identifiers><api:identifier scheme="pubmed">10717248</api:identifier></api:identifiers></api:field><api:field name="field-citation-ratio" type="decimal" display-name="Field citation ratio"><api:decimal>0.71</api:decimal></api:field><api:field name="issn" type="text" display-name="ISSN"><api:text>1019-6439</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/974000"/></api:links></api:field><api:field name="issue" type="text" display-name="Issue"><api:text>4</api:text></api:field><api:field name="journal" type="text" display-name="Journal"><api:text>International Journal of Oncology</api:text></api:field><api:field name="keywords" type="keyword-list" display-name="Keywords"><api:keywords><api:keyword scheme="for-2020">32 Biomedical and Clinical Sciences</api:keyword><api:keyword scheme="for-2020">3201 Cardiovascular Medicine and Haematology</api:keyword><api:keyword scheme="for-2020">3202 Clinical Sciences</api:keyword><api:keyword scheme="for-2020">3211 Oncology and Carcinogenesis</api:keyword><api:keyword scheme="rcdc">Rare Diseases</api:keyword><api:keyword scheme="rcdc">Clinical Trials and Supportive Activities</api:keyword><api:keyword scheme="rcdc">Lymphoma</api:keyword><api:keyword scheme="rcdc">Clinical Research</api:keyword><api:keyword scheme="rcdc">Cancer</api:keyword><api:keyword scheme="rcdc">Hematology</api:keyword><api:keyword scheme="rcdc">Neurodegenerative</api:keyword><api:keyword scheme="hrcs-rac">6.1 Pharmaceuticals</api:keyword><api:keyword scheme="hrcs-rac">6 Evaluation of treatments and therapeutic interventions</api:keyword><api:keyword scheme="hrcs-hc">Cancer</api:keyword><api:keyword scheme="mesh">Adult</api:keyword><api:keyword scheme="mesh">Aged</api:keyword><api:keyword scheme="mesh">Aged, 80 and over</api:keyword><api:keyword scheme="mesh">Antineoplastic Combined Chemotherapy Protocols</api:keyword><api:keyword scheme="mesh">Dexamethasone</api:keyword><api:keyword scheme="mesh">Epirubicin</api:keyword><api:keyword scheme="mesh">Female</api:keyword><api:keyword scheme="mesh">Humans</api:keyword><api:keyword scheme="mesh">Lymphoma, Non-Hodgkin</api:keyword><api:keyword scheme="mesh">Male</api:keyword><api:keyword scheme="mesh">Middle Aged</api:keyword><api:keyword scheme="mesh">Palliative Care</api:keyword><api:keyword scheme="mesh">Vincristine</api:keyword></api:keywords></api:field><api:field name="online-publication-date" type="date" display-name="Online publication date"><api:date><api:day>1</api:day><api:month>4</api:month><api:year>2000</api:year></api:date></api:field><api:field name="open-access-status" type="text" display-name="Open access status"><api:text>Closed Access</api:text></api:field><api:field name="pagination" type="pagination" display-name="Pagination"><api:pagination><api:begin-page>777</api:begin-page><api:end-page>782</api:end-page></api:pagination></api:field><api:field name="publication-date" type="date" display-name="Publication date"><api:date><api:month>4</api:month><api:year>2000</api:year></api:date></api:field><api:field name="publisher" type="text" display-name="Publisher"><api:text>Spandidos Publications</api:text></api:field><api:field name="record-created-at-source-date" type="date" display-name="Record created at source"><api:date><api:day>31</api:day><api:month>8</api:month><api:year>2017</api:year></api:date></api:field><api:field name="relative-citation-ratio" type="decimal" display-name="Relative citation ratio"><api:decimal>0.14</api:decimal></api:field><api:field name="title" type="text" display-name="Title"><api:text>VEDex (vincristine, epirubicin dexamethasone): an effective and well tolerated palliative chemotherapy regimen for non-Hodgkin's lymphoma.</api:text></api:field><api:field name="volume" type="text" display-name="Volume"><api:text>16</api:text></api:field></api:native></api:record><api:record format="native" id="241383" source-id="11" source-name="wos-lite" source-display-name="Web of Science (Lite)" id-at-source="WOS:000085926100018" last-modified-when="2024-03-14T05:57:11.25+00:00"><api:citation-count>5</api:citation-count><api:native><api:field name="authors" type="person-list" display-name="Authors"><api:people><api:person><api:last-name>El Helw</api:last-name><api:initials>LM</api:initials><api:first-names>LM</api:first-names><api:separate-first-names><api:first-name>L</api:first-name><api:first-name>M</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Lorigan</api:last-name><api:initials>PC</api:initials><api:first-names>PC</api:first-names><api:separate-first-names><api:first-name>P</api:first-name><api:first-name>C</api:first-name></api:separate-first-names><api:identifiers><api:identifier scheme="researcherid">J-6898-2015</api:identifier></api:identifiers></api:person><api:person><api:links><api:link type="elements/user" id="1603" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/1603"/></api:links><api:last-name>Robinson</api:last-name><api:initials>MH</api:initials><api:first-names>MH</api:first-names><api:separate-first-names><api:first-name>M</api:first-name><api:first-name>H</api:first-name></api:separate-first-names></api:person><api:person><api:links><api:link type="elements/user" id="1991" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/1991"/></api:links><api:last-name>Coleman</api:last-name><api:initials>RE</api:initials><api:first-names>RE</api:first-names><api:separate-first-names><api:first-name>R</api:first-name><api:first-name>E</api:first-name></api:separate-first-names></api:person><api:person><api:links><api:link type="elements/user" id="18786" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/18786"/></api:links><api:last-name>Hancock</api:last-name><api:initials>BW</api:initials><api:first-names>BW</api:first-names><api:separate-first-names><api:first-name>B</api:first-name><api:first-name>W</api:first-name></api:separate-first-names></api:person></api:people></api:field><api:field name="author-url" type="text" display-name="Link 1"><api:text>https://www.webofscience.com/api/gateway?GWVersion=2&amp;SrcApp=sheffield_elements_live&amp;SrcAuth=WosAPI&amp;KeyUT=WOS:000085926100018&amp;DestLinkType=FullRecord&amp;DestApp=WOS_CPL</api:text></api:field><api:field name="external-identifiers" type="identifier-list" display-name="External identifiers"><api:identifiers><api:identifier scheme="isidoc">294TH</api:identifier><api:identifier scheme="pubmed">10717248</api:identifier></api:identifiers></api:field><api:field name="issn" type="text" display-name="ISSN"><api:text>1019-6439</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/974000"/></api:links></api:field><api:field name="issue" type="text" display-name="Issue"><api:text>4</api:text></api:field><api:field name="journal" type="text" display-name="Journal"><api:text>INTERNATIONAL JOURNAL OF ONCOLOGY</api:text></api:field><api:field name="keywords" type="keyword-list" display-name="Keywords"><api:keywords><api:keyword>non-Hodgkin's lymphoma</api:keyword><api:keyword>palliative chemotherapy</api:keyword></api:keywords></api:field><api:field name="pagination" type="pagination" display-name="Pagination"><api:pagination><api:begin-page>777</api:begin-page><api:end-page>782</api:end-page></api:pagination></api:field><api:field name="publication-date" type="date" display-name="Publication date"><api:date><api:year>2000</api:year></api:date></api:field><api:field name="publication-status" type="text" display-name="Status"><api:text>Published</api:text></api:field><api:field name="title" type="text" display-name="Title"><api:text>VEDex (vincristine, epirubicin dexamethasone): an effective and well tolerated palliative chemotherapy regimen for non-Hodgkin's lymphoma</api:text></api:field><api:field name="types" type="list" display-name="Sub types"><api:items><api:item>Article</api:item></api:items></api:field><api:field name="volume" type="text" display-name="Volume"><api:text>16</api:text></api:field></api:native></api:record><api:record format="native" id="24349" source-id="3" source-name="wos" source-display-name="Web of Science" id-at-source="WOS:000085926100018" last-modified-when="2014-07-25T11:06:04.157+01:00"><api:citation-count>4</api:citation-count><api:native><api:field name="authors" type="person-list" display-name="Authors"><api:people><api:person><api:last-name>El Helw</api:last-name><api:initials>LM</api:initials><api:first-names>LM</api:first-names><api:separate-first-names><api:first-name>L</api:first-name><api:first-name>M</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Lorigan</api:last-name><api:initials>PC</api:initials><api:first-names>PC</api:first-names><api:separate-first-names><api:first-name>P</api:first-name><api:first-name>C</api:first-name></api:separate-first-names></api:person><api:person><api:links><api:link type="elements/user" id="1603" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/1603"/></api:links><api:last-name>Robinson</api:last-name><api:initials>MH</api:initials><api:first-names>MH</api:first-names><api:separate-first-names><api:first-name>M</api:first-name><api:first-name>H</api:first-name></api:separate-first-names></api:person><api:person><api:links><api:link type="elements/user" id="1991" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/1991"/></api:links><api:last-name>Coleman</api:last-name><api:initials>RE</api:initials><api:first-names>RE</api:first-names><api:separate-first-names><api:first-name>R</api:first-name><api:first-name>E</api:first-name></api:separate-first-names></api:person><api:person><api:links><api:link type="elements/user" id="18786" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/18786"/></api:links><api:last-name>Hancock</api:last-name><api:initials>BW</api:initials><api:first-names>BW</api:first-names><api:separate-first-names><api:first-name>B</api:first-name><api:first-name>W</api:first-name></api:separate-first-names></api:person></api:people></api:field><api:field name="issn" type="text" display-name="ISSN"><api:text>1019-6439</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/974000"/></api:links></api:field><api:field name="issue" type="text" display-name="Issue"><api:text>4</api:text></api:field><api:field name="journal" type="text" display-name="Journal"><api:text>INT J ONCOL</api:text></api:field><api:field name="keywords" type="keyword-list" display-name="Keywords"><api:keywords><api:keyword>non-Hodgkin's lymphoma</api:keyword><api:keyword>palliative chemotherapy</api:keyword><api:keyword>COMBINATION CHEMOTHERAPY</api:keyword><api:keyword>RELAPSING LYMPHOMA</api:keyword><api:keyword>LOW TOXICITY</api:keyword><api:keyword>PHASE-II</api:keyword><api:keyword>MITOXANTRONE</api:keyword><api:keyword>ETOPOSIDE</api:keyword></api:keywords></api:field><api:field name="pagination" type="pagination" display-name="Pagination"><api:pagination><api:begin-page>777</api:begin-page><api:end-page>782</api:end-page></api:pagination></api:field><api:field name="publication-date" type="date" display-name="Publication date"><api:date><api:month>4</api:month><api:year>2000</api:year></api:date></api:field><api:field name="title" type="text" display-name="Title"><api:text>VEDex (vincristine, epirubicin dexamethasone): an effective and well tolerated palliative chemotherapy regimen for non-Hodgkin's lymphoma</api:text></api:field><api:field name="volume" type="text" display-name="Volume"><api:text>16</api:text></api:field></api:native></api:record></api:records><api:fields/><api:all-labels type="keyword-list"><api:keywords><api:keyword scheme="mesh" origin="record-data" source="pubmed">Adult</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Aged</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Aged, 80 and over</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Antineoplastic Combined Chemotherapy Protocols</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Dexamethasone</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Epirubicin</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Female</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Humans</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Lymphoma, Non-Hodgkin</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Male</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Middle Aged</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Palliative Care</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Vincristine</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Humans</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Lymphoma, Non-Hodgkin</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Vincristine</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Epirubicin</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Dexamethasone</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Antineoplastic Combined Chemotherapy Protocols</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Palliative Care</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Adult</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Aged</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Aged, 80 and over</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Middle Aged</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Female</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Male</api:keyword><api:keyword scheme="for-2020" origin="record-data" source="dimensions">32 Biomedical and Clinical Sciences</api:keyword><api:keyword scheme="for-2020" origin="record-data" source="dimensions">3201 Cardiovascular Medicine and Haematology</api:keyword><api:keyword scheme="for-2020" origin="record-data" source="dimensions">3202 Clinical Sciences</api:keyword><api:keyword scheme="for-2020" origin="record-data" source="dimensions">3211 Oncology and Carcinogenesis</api:keyword><api:keyword scheme="rcdc" origin="record-data" source="dimensions">Rare Diseases</api:keyword><api:keyword scheme="rcdc" origin="record-data" source="dimensions">Clinical Trials and Supportive Activities</api:keyword><api:keyword scheme="rcdc" origin="record-data" source="dimensions">Lymphoma</api:keyword><api:keyword scheme="rcdc" origin="record-data" source="dimensions">Clinical Research</api:keyword><api:keyword scheme="rcdc" origin="record-data" source="dimensions">Cancer</api:keyword><api:keyword scheme="rcdc" origin="record-data" source="dimensions">Hematology</api:keyword><api:keyword scheme="rcdc" origin="record-data" source="dimensions">Neurodegenerative</api:keyword><api:keyword scheme="hrcs-rac" origin="record-data" source="dimensions">6.1 Pharmaceuticals</api:keyword><api:keyword scheme="hrcs-rac" origin="record-data" source="dimensions">6 Evaluation of treatments and therapeutic interventions</api:keyword><api:keyword scheme="hrcs-hc" origin="record-data" source="dimensions">Cancer</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Adult</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Aged</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Aged, 80 and over</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Antineoplastic Combined Chemotherapy Protocols</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Dexamethasone</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Epirubicin</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Female</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Humans</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Lymphoma, Non-Hodgkin</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Male</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Middle Aged</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Palliative Care</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Vincristine</api:keyword><api:keyword origin="record-data" source="wos-lite">non-Hodgkin's lymphoma</api:keyword><api:keyword origin="record-data" source="wos-lite">palliative chemotherapy</api:keyword><api:keyword origin="record-data" source="wos">non-Hodgkin's lymphoma</api:keyword><api:keyword origin="record-data" source="wos">palliative chemotherapy</api:keyword><api:keyword origin="record-data" source="wos">COMBINATION CHEMOTHERAPY</api:keyword><api:keyword origin="record-data" source="wos">RELAPSING LYMPHOMA</api:keyword><api:keyword origin="record-data" source="wos">LOW TOXICITY</api:keyword><api:keyword origin="record-data" source="wos">PHASE-II</api:keyword><api:keyword origin="record-data" source="wos">MITOXANTRONE</api:keyword><api:keyword origin="record-data" source="wos">ETOPOSIDE</api:keyword><api:keyword scheme="for" origin="issn-inferred">1112 Oncology and Carcinogenesis</api:keyword><api:keyword scheme="science-metrix" origin="issn-inferred">Oncology &amp; Carcinogenesis</api:keyword><api:keyword scheme="for-2020" origin="issn-inferred">3101 Biochemistry and cell biology</api:keyword><api:keyword scheme="for-2020" origin="issn-inferred">3211 Oncology and carcinogenesis</api:keyword></api:keywords></api:all-labels><api:journal issn="1019-6439" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/974000" title="International Journal of Oncology"><api:records><api:record source-name="summary"><api:title>International Journal of Oncology</api:title></api:record></api:records></api:journal><api:relationships href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/publications/854/relationships"/></api:object></api:result></api:response>